Clinical Trial Update: Study of BSF 208075 Evaluating Exercise Capacity in Patients With Pulmonary Arterial Hypertension [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating BSF 208075 on exercise capacity in patients with pulmonary arterial hypertension has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Arterial Hypertension

Drugs mentioned

• BSF 208075

Snippet

Sponsor: Gilead Sciences | Conditions: Pulmonary Hypertension | Phase 2 | Status: COMPLETED